Krishna Institute Of Medical Sciences Limited · NSE:KIMS
Krishna Institute Of Medical Sciences — Q4 FY2023 Earnings Presentation
31 slides from Krishna Institute Of Medical Sciences's earnings presentation, May 18, 2023
Slide 1: Cover letter to stock exchanges: Investor presentation
18th May 2023 The General Manager, The Manager, Department of Corporate services Listing Department Bombay Stock Exchange Ltd (BSE) National Stock Exchange of India Limited, Phiroze Jheejheebhoy Towers, Exchange Plaza, 5th Floor, Dalal Street, Plot No.C/1, 'G' Block, Mumbai - 400 001. Bandra - Kurla
Slide 2: Making Quality Healthcare Accessible & Affordable - Q4 FY23 Update
MAKING QUALITY HEALTHCARE ACCESSIBLE & AFFORDABLE Q4 FY23 UPDATE Private & Confidential
Slide 3: Driven by a Vision
Driven by a Vision Affordable Quality Care VISION: Best-in-Class Facilities Patient Centric Systems & Processes S To be the most preferred NT healthcare services brand by TIE providing affordable care and best PA clinical outcomes to patients. Clinical Outcome Driven Excellence And to be the best pl
Slide 4: Multi Specialty Care
Multi Specialty Care Brain Eyes Bones and Spine Radiology • Neurology • Ophthalmology • Orthopedics • Imaging • Neurosurgery Gastro Intestinal Tract • Arthroscopic Surgery • Interventional Radiology • Psychiatry • Medical Gastroenterology • Spine Surgery Lab Services • Neuro Rehabilitation • Surgica
Slide 5: KIMS at a Glance
KIMS at a Glance Telangana Secunderabad (1000) Maharashtra Paradise Circle (290) Nagpur (334) Kondapur (200) Nashik (Under Construction) Gachibowli (237) Andhra Pradesh Visakhapatnam (434) Srikakulam (200) Rajahmundry (195) Karnataka Ongole (350) Bengaluru Kurnool (200) (Under Construction) Nellore
Slide 6: Dr. B. Bhaskar Rao - Visionary Behind KIMS
Dr. B. Bhaskar Rao - Visionary Behind KIMS Managing Director A legend in CT Surgery, Dr. Bollineni Bhaskar Rao {MBBS, MS, DNB (CT Surgery)} is one of the very few Cardio- Thoracic Surgeons in the country, who performed over 30000 surgeries in his career spanning over more than 25 years. Well known i
Slide 7: Dr. Abhinay Bollineni
Dr. Abhinay Bollineni Chief Executive Officer Dr. Abhinay Bollineni joined KIMS Hospitals in 2013 and spent the next couple of years in Hospital Operations before taking charge of Strategy & Marketing for the Group in 2015. In a short span of 5 years, KIMS expanded and opened five additional units (
Slide 8: Board of Directors
Board of Directors Mr. Rajeswara Rao G Dr. Bhaskara Rao Bollineni Dr. Abhinay Bollineni Mrs. Anitha Dandamudi Shantanu Rastogi Independent Director, Managing Director Chief Executive Officer Whole-time Director Non-Executive Director Chairman (Stakeholders’ Relationship Committee) Mr. Saumen Chakrab
Slide 9: Shareholding Pattern - 31 March, 2023
Shareholding Pattern - 31 March, 2023 st Retail & Others, Retail Pre IPO, 3.0% 8.5% Promoter & Promoter Group, 38.8% Share Holder No of Shares Share Holding % Category Promoter 3,10,86,304 38.8% General Atlantica 68,89,147 8.6% ICICI Ventures 19,39,393 2.4% FII, 10.8% Mirae Asset MF 67,75,617 8.5% D
Slide 10: Modern Medical Technology
Modern Medical Technology 4-Arm HD da Vinci O-Arm Scanner Spy Glass Fibroscan Robotic Surgical Multi-dimensional surgical State of the art add on to Specialized non-invasive System imaging platform optimized ERCP that allows doctors to diagnostic ultrasound-based Facilitates complex for use in spine
Slide 11: Many Firsts...
Many Firsts... • First in Asia in to do Trans catheter • India’s first COVID Double Lung • Number 1 in Nephrology treatments in Tricuspid Valve replacement transplant done in 2020 Andhra Pradesh* procedure done in 2018 • India’s first Breathing Lung transplant • Number 1 in Neurosurgery & Poly • Lar
Slide 12: Key Accomplishments
Key Accomplishments Pharmacie De Qualite (PDQ) ‘Best Patient Friendly Hospital’ ‘Best Hospital to Work For’ Certification Overall PDQ Evaluation Ranked No. 1 Hospital AHPI Health Care Excellence AHPI Global Conclave Performance Score - 98% by Times of India, Hyderabad Award (2017) Award (2019) Gradi
Slide 13: Consistent performer over 2 decades
Consistent performer over 2 decades (Rupees in Millions) 5,766 22,235 5,217*** 16,711 % 11,287 % 4 27.9 31 . GR: GR : C A A C 2,412 4,280 773 1,311 317 263 42 2005 2010 2015 2020 2022 2023** 2005 2010 2015 2020 2022 2023** No. of No. of No. of No. of No. of No. of Hospitals: 1 Hospitals: 1 Hospitals
Slide 14: Q4 FY23 Updates
Q4 FY23 Updates 13 Private & Confidential
Slide 15: Financial & Operational Highlights - 1/2
Financial & Operational Highlights - 1/2 (Rupees in Millions) FINANCIAL HIGHLIGHTS Q4 FY 23 Consolidated • Company achieved highest ever Consolidated Quarterly Revenue, EBITDA, PBT & PAT • Consolidated Quarterly Revenue from Operations and EBITDA grew by 54.7% and 38.8%, respectively, on a YoY basis
Slide 16: Financial & Operational Highlights - 2/2
Financial & Operational Highlights - 2/2 FINANCIAL HIGHLIGHTS Q4 FY 23 Consolidated • Consolidated Revenue from operations grew by 54.7% YoY basis and 2.4% on QoQ basis to Rs. 5,759.2 mn • Consolidated EBITDA (Pre-INDAS and Other Income) grew by 38.8% on a YoY basis and 8.3% on a QoQ basis to Rs. 15
Slide 17: Digital & ESG Initiatives
Digital & ESG Initiatives DIGITAL INITIATIVES During the last quarter, KIMS continued its digitization journey with a goal of having 100% paperless business process in all its operational, clinical and finance verticals. As part of this journey, last quarter we have either initiated or delivered the
Slide 18: Group Operating Performance - 1/3
Group Operating Performance - 1/3 IP VOLUME (‘000) (1.7%) OP VOLUME (‘000) (0.2%) 177 46 45 1462 382 381 137 117 33 1014 271 830 FY21 FY22 FY23 Q4 FY22 Q3 FY23 Q4 FY23 FY21 FY22 FY23 Q4 FY22 Q3 FY23 Q4 FY23 OCCUPANCY* ARPOB (‘000) 2.6% 2.6% 79.8% 73.9% 29.9 30.6 78.6% 70.8% 29.8 68.2% 25.3 25.1 69.3
Slide 19: Group Operating Performance - 2/3
Group Operating Performance - 2/3 (Rupees in Millions) TOTAL REVENUE EBITDA* 2.1% 8.3% 22,235 5,808 5,766 1,563 5,686 1,444 5,122 16,711 3,805 1,127 13,401 3,672 FY21 FY22 FY23 Q4 FY22 Q3 FY23 Q4 FY23 FY21 FY22 FY23 Q4 FY22 Q3 FY23 Q4 FY23 PBT** 12.8% PAT** 20.6% 4,701 1,273 3,510 987 4,473 1,128 3,
Slide 20: Group Operating Performance - 3/3
Group Operating Performance - 3/3 Particulars FY21 FY22 FY23 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 Bed Capacity 3,064 3,064 3,940 3,666 4,015 4,015 3,940 Operational Beds 2,590 2,590 3,468 3,222 3,543 3,543 3,468 Census Beds 2,246 2,246 2,960 2,760 3,026 3,026 2,960 Non Census Beds 344 344 508 462 517 517
Slide 21: Comparison of Telangana and Andhra Pradesh Matured Hospitals - 1/2
Comparison of Telangana and Andhra Pradesh Matured Hospitals - 1/2 Telangana (KIMS) AP Matured Assets Particulars FY21 FY22 Q1 FY 23 Q2 FY23 Q3 FY23 Q4 FY23 FY23 FY21 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 FY23 Bed Capacity 1,200 1,200 1,200 1,200 1,200 1,200 1,200 630 630 630 645 645 645 645 Operatio
Slide 22: Comparison of Andhra Pradesh Acquired, Sunshine & Nagpur - 2/2
Comparison of Andhra Pradesh Acquired, Sunshine & Nagpur - 2/2 AP Acquired Assets Sunshine Nagpur Group Particulars FY21 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 FY23 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 FY23 Q2 FY23** Q3 FY23 Q4 FY23 FY23 FY21 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 FY23 Bed Capacity 1234 1234
Slide 23: Speciality Mix
Speciality Mix Others Cardiac Science 25% 18% Renal Sciences 8% Mother & Child 9% Group FY 23 Organ Oncology Transplant 5% 3% Gastric Sciences 8% Neuro Sciences 11% Orthopaedics 13% Includes Sunshine and 7 months (Sep’22 -Mar'23) of Nagpur 22 Private & Confidential
Slide 24: Payor & Cluster Profile
Payor & Cluster Profile PAYOR MIX CLUSTER TOTAL REVENUE Maharashtra AP Mature 4.0% 10.8% Aarogyasri 8% AP Non Mature 15.9% Corporate Cash Group 12% 54% FY23 Telangana 69.3% Group FY23 CLUSTER EBITDA* Maharashtra AP Mature Insurance 0.8% 13.1% 26% AP Non Mature 11.6% Group FY23 *EBITDA before IND AS
Slide 25: Key Achievements in Q4 FY23
Key Achievements in Q4 FY23 24 Private & Confidential
Slide 26: Key Achievements in Q4 FY23
Key Achievements in Q4 FY23 25 Private & Confidential
Slide 27: Key to our success
Key to our success Doctor Affordable Partnerships Quality Care Modern Medical Infra 26 Private & Confidential
Slide 28: KIMS has a disciplined growth strategy in adjacent markets
KIMS has a disciplined growth strategy - strategically grow in adjacent markets some of which are ‘natural extensions’ KIMS Plans to Grow into Markets that are Adjacent to the Current Core Markets of AP and Telangana Central & Western India (Indore, Aurangabad, Nagpur & Raipur): KIMS flagship hospit
Slide 29: Profit and Loss Statement
Profit and Loss Statement (Rupees in Millions) Consolidated Particulars Q4 FY 23 Q3 FY 23 Q4 FY 22 QoQ(%) YoY(%) FY 23 FY 22 YoY(%) Operating Revenue 5,759 5,622 3,723 2.4% 54.7% 21,977 16,508 33.1% Other Income 49 64 82 -24.1% -40.2% 259 203 27.7% Total Revenue 5,808 5,686 3,805 2.1% 52.6% 22,235 1
Slide 30: Corporate Structure (As on 31 March'23)
Corporate Structure (As on 31 March'23) st Krishna Institute of Medical Sciences Ltd. KIMS Secunderabad KIMS Nellore KIMS Rajahmundry KIMS Ongole (100%) (100%) (100%) (100%) AHPL KHEPL KIMS ICON KIMS Saveera KIMS Sarvejana KIMS-Manavata SPANV KIMS Hospitals Srikakulam Kondapur Vizag Anantapur Kurnoo
Slide 31: Thank You
Thank You 30 Private & Confidential
Krishna Institute of Medical Sciences — Q4 FY2023 Earnings Presentation on 6ix